Get the Stockscreener App
2.77
2.46%
-0.07
Trevi Therapeutics Inc stock is currently priced at $2.77, with a 24-hour trading volume of 65,267.
It has seen a -2.46% decreased in the last 24 hours and a +7.36% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $2.81 pivot point. If it approaches the $2.72 support level, significant changes may occur.
Previous Close:
$2.84
Open:
$2.85
24h Volume:
65,267
Market Cap:
$195.11M
Revenue:
-
Net Income/Loss:
$-29.07M
P/E Ratio:
-8.9355
EPS:
-0.31
Net Cash Flow:
$-31.85M
1W Performance:
+1.47%
1M Performance:
+7.36%
6M Performance:
+99.28%
1Y Performance:
+13.06%
1D Range:
$2.75
$2.93
52W Range:
$0.97
$4.00
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Name
Trevi Therapeutics Inc
Sector
Industry
Phone
203-304-2499
Address
195 Church Street, 14th Floor, New Haven, CT
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-12-23 | Initiated | B. Riley Securities | Buy |
| Nov-22-22 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | BMO Capital Markets | Outperform |
| Jun-03-19 | Initiated | Needham | Buy |
| Jun-03-19 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | Stifel | Buy |
View All
Trevi Therapeutics Inc Stock (TRVI) Latest News
Trevi Therapeutics CEO sells shares worth over $13,000 By Investing.com - Investing.com
Investing.com
Are You Looking for a Top Momentum Pick? Why Trevi Therapeutics, Inc. (TRVI) is a Great Choice - Yahoo News Australia
Yahoo News Australia
Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Sells $13,276.20 in Stock - MarketBeat
MarketBeat
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2024 Earnings Call Transcript - Insider Monkey
Insider Monkey
Earnings call: Trevi Therapeutics reports progress in clinical trials - Investing.com South Africa
Investing.com South Africa
Trevi Therapeutics (NASDAQ:TRVI) Rating Reiterated by Needham & Company LLC - Defense World
Defense World
Trevi Therapeutics Inc Stock (TRVI) Financials Data
Trevi Therapeutics Inc (TRVI) Net Income 2024
TRVI net income (TTM) was -$29.07 million for the quarter ending December 31, 2023, a +0.30% increase year-over-year.
Trevi Therapeutics Inc (TRVI) Cash Flow 2024
TRVI recorded a free cash flow (TTM) of -$31.85 million for the quarter ending December 31, 2023, a -12.40% decrease year-over-year.
Trevi Therapeutics Inc (TRVI) Earnings per Share 2024
TRVI earnings per share (TTM) was -$0.29 for the quarter ending December 31, 2023, a +48.21% growth year-over-year.
Trevi Therapeutics Inc Stock (TRVI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GOOD JENNIFER L | President & CEO |
May 10 '24 |
Sale |
2.90 |
4,578 |
13,276 |
213,313 |
| Delfini Lisa | Chief Financial Officer |
Oct 11 '23 |
Option Exercise |
0.51 |
2,292 |
1,171 |
36,686 |
| Delfini Lisa | Chief Financial Officer |
Oct 11 '23 |
Sale |
2.02 |
785 |
1,586 |
35,901 |
| Delfini Lisa | Chief Financial Officer |
Sep 11 '23 |
Option Exercise |
0.51 |
2,291 |
1,171 |
35,105 |
| Delfini Lisa | Chief Financial Officer |
Sep 11 '23 |
Sale |
2.20 |
711 |
1,564 |
34,394 |
| Delfini Lisa | Chief Financial Officer |
Aug 11 '23 |
Option Exercise |
0.51 |
2,292 |
1,171 |
33,496 |
| Delfini Lisa | Chief Financial Officer |
Aug 11 '23 |
Sale |
2.36 |
682 |
1,610 |
32,814 |
| Delfini Lisa | Chief Financial Officer |
Jul 11 '23 |
Option Exercise |
0.51 |
2,292 |
1,171 |
31,891 |
| Delfini Lisa | Chief Financial Officer |
Jul 11 '23 |
Sale |
2.34 |
687 |
1,608 |
31,204 |
| Simon Farrell | Chief Commercial Officer |
Jun 20 '23 |
Option Exercise |
0.51 |
6,250 |
3,194 |
45,650 |
About Trevi Therapeutics Inc
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company's nalbuphine ER, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. Trevi Therapeutics, Inc. was founded in 2011 and is headquartered in New Haven, Connecticut.
0.77%
1.20%
Cap:
|
Volume (24h):